This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): CCR5 mAb, CCR5mAb004

Description: HGS' CCR5 human monoclonal antibodies bind specifically and with high affinity to the CCR5 receptor and prevent entry of the HIV-1 retrovirus into the cell. The CCR5 receptor is a co-receptor on the cell surface that, together with CD4, mediates the binding of HIV-1 and its entry into the cell.

Deal Structure: In May 2003, HGS announced the acquisition of an exclusive worldwide license from Abgenix to develop and commercialize a fully human monoclonal antibody to the CCR5 receptor. HGS will pay milestone and royalty payments for HGS004 as it is developed and if it is commercialized.

In April 2006, Abgenix was acquired by Amgen.

In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.

Partners: Amgen, Inc.

HGS004 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug